HZNP - Horizon Therapeutics Plc Stock Price, Fair Value and News

116.30USD0.00 (0.00%)Market Closed

Market Summary

USD116.300.00

Market Closed

0.00%

HZNP Stock Price

View Fullscreen

HZNP RSI Chart

HZNP Valuation

Market Cap

26.6B

Price/Earnings (Trailing)

60.8

Price/Sales (Trailing)

7.31

EV/EBITDA

25.73

Price/Free Cashflow

27.79

HZNP Price/Sales (Trailing)

HZNP Profitability

Free Cashflow Yield

3.6%

HZNP Fundamentals

HZNP Revenue

HZNP Earnings

Breaking Down HZNP Revenue

How does HZNP drawdown profile look like?

HZNP Financial Health

HZNP Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.6B	3.6B	0	0
2022	3.8B	3.8B	3.7B	3.6B
2021	2.2B	2.6B	3.0B	3.2B
2020	1.4B	1.5B	1.8B	2.2B
2019	1.3B	1.3B	1.3B	1.3B
2018	1.1B	1.1B	1.1B	1.2B
2017	997.3M	1.0B	1.1B	1.1B
2016	848.6M	933.1M	915.3M	981.1M
2015	358.2M	464.9M	616.3M	757.0M
2014	117.2M	172.2M	223.2M	297.0M
2013	24.6M	31.2M	48.0M	74.0M
2012	8.1M	11.3M	18.4M	18.8M
2011	3.5M	4.7M	5.8M	6.9M
2010	0	0	0	2.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Horizon Therapeutics Plc

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

CEO	Mr. Timothy P. Walbert
WEBSITE	horizontherapeutics.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2190

Horizon Therapeutics Plc Frequently Asked Questions

What is the ticker symbol for Horizon Therapeutics Plc? What does HZNP stand for in stocks?

HZNP is the stock ticker symbol of Horizon Therapeutics Plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Horizon Therapeutics Plc (HZNP)?

As of Wed Apr 03 2024, market cap of Horizon Therapeutics Plc is 26.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HZNP stock?

You can check HZNP's fair value in chart for subscribers.

Is Horizon Therapeutics Plc a good stock to buy?

The fair value guage provides a quick view whether HZNP is over valued or under valued. Whether Horizon Therapeutics Plc is cheap or expensive depends on the assumptions which impact Horizon Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HZNP.

What is Horizon Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 03 2024, HZNP's PE ratio (Price to Earnings) is 60.8 and Price to Sales (PS) ratio is 7.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HZNP PE ratio will change depending on the future growth rate expectations of investors.